Ascentage Pharma Group International (AAPG) Non-Current Deferred Tax Liability: 2022-2024

  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability fell 25.35% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year decrease of 25.35%. This contributed to the annual value of $1.7 million for FY2024, which is 84.31% down from last year.
  • As of Q4 2024, Ascentage Pharma Group International's Non-Current Deferred Tax Liability stood at $1.7 million, which was down 25.35% from $2.2 million recorded in Q4 2023.
  • Over the past 5 years, Ascentage Pharma Group International's Non-Current Deferred Tax Liability peaked at $2.5 million during Q4 2022, and registered a low of $1.7 million during Q4 2024.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $2.2 million (2023), whereas its average is $2.1 million.
  • Data for Ascentage Pharma Group International's Non-Current Deferred Tax Liability shows a maximum YoY dropped of 25.35% (in 2024) over the last 5 years.
  • Ascentage Pharma Group International's Non-Current Deferred Tax Liability (Quarterly) stood at $2.5 million in 2022, then fell by 9.79% to $2.2 million in 2023, then declined by 25.35% to $1.7 million in 2024.
  • Its Non-Current Deferred Tax Liability stands at $1.7 million for Q4 2024, versus $2.2 million for Q4 2023 and $2.5 million for Q4 2022.